Canagliflozin-associated severe hyponatremia: a rare and potentially adverse effect?
Maheswaran DhanasekaranSiddharth NarayananIoannis MastorisSuchita MehtaPublished in: Endocrinology, diabetes & metabolism case reports (2022)
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are usually well-tolerated, but some serious adverse effects have been documented. Our case report suggests hyponatremia as a potential, rare side effect of SGLT2i and makes physicians aware of the occurrence of such life-threatening but preventable complications. Timely and close monitoring of the patient, with temporary discontinuation of this drug, may be recommended towards effective management. Studies demonstrating a comprehensive understanding of SGLT2i-related electrolyte derangements are warranted.